Patent application number | Description | Published |
20090280176 | CONTROLLED RELEASE FORMULATIONS OF ALPRAZOLAM - A controlled release formulation of alprazolam for once a day administration to a mammalian subject, which formulation releases alprazolam along a pre-determined release profile, is provided. | 11-12-2009 |
20090304794 | CONTROLLED RELEASE FORMULATIONS OF PRAMIPEXOLE - A controlled release formulation of pramipexole for once-a-day administration to a mammalian subject, which formulation releases pramipexole along a pre-determined release profile, is provided. | 12-10-2009 |
20110003870 | METHOD OF TREATMENT OF A NEUROLOGICAL DISORDER - A method of treating neurological conditions, such as Parkinson's Disease and Restless Leg Syndrome, in a mammalian subject is disclosed. The method comprises the administration of a once-a-day controlled release formulation of pramipexole, which formulation provides a consistently ascending PK profile during sleeping hours. | 01-06-2011 |
20110244042 | STABILIZED FORMULATIONS OF CNS COMPOUNDS - Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone. | 10-06-2011 |
20110287099 | Sustained-release formulations of topiramate - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 11-24-2011 |
20110287103 | Sustained-release formulations of topiramate - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 11-24-2011 |
20120321708 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 12-20-2012 |
20130202661 | FORMULATIONS OF VILOXAZINE - Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed. | 08-08-2013 |
20140322343 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 10-30-2014 |
20150017249 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 01-15-2015 |
20150086629 | STABILIZED FORMULATIONS OF CNS COMPOUNDS - Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone. | 03-26-2015 |